Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports

Anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs), combined with bevacizumab and platinum-based chemotherapy, have shown promising efficacy in treating metastatic non-squamous cell lung cancer in phase 3 clinical trials. However, drug-induced nephro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Ping-Chih, Chen, Tai-Di, Tsai, Tsung-Yu, Yang, Cheng-Ta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955069/
https://www.ncbi.nlm.nih.gov/pubmed/36826160
http://dx.doi.org/10.3390/clinpract13010018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9955069/
https://www.ncbi.nlm.nih.gov/pubmed/36826160
http://dx.doi.org/10.3390/clinpract13010018

Ejemplares similares